The small Virginia company Kaleo makes an injector device called Evzio that is suddenly in demand because of the nation's epidemic use of opioids. Evzio is used to deliver naloxone, a life-saving antidote to overdoses of opioids. More than 33,000 people are believed to have died from such overdoses in 2015. As demand for Kaleo's product has grown, the privately held firm has raised its twin-pack price to $4,500, up from $690 in 2014. Evzio talks users through the process as they inject naloxone. The company says the talking device is worth the price because it can guide anyone to inject an overdose victim correctly, leave the needle in for the right amount of time, and potentially save his or her life. The Kaleo product accounted for nearly 20% of the naloxone dispensed between 2015 and 2016, and for nearly one-half of all naloxone products prescribed to patients between the ages of 40 and 64 years. Advocates and pharmacy groups have made videos touting the product. Industry observers, however, say the device's price surge is way out of step with production costs.